A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC).
Phase of Trial: Phase II
Latest Information Update: 29 May 2018
At a glance
- Drugs Timolumab (Primary)
- Indications Primary sclerosing cholangitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms BUTEO
- 10 Jun 2017 Biomarkers information updated
- 02 May 2017 Planned End Date changed from 1 Feb 2018 to 1 Mar 2019.
- 02 May 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2019.